PAREXEL International Corporation (PRXL) : 5 brokerage houses believe that PAREXEL International Corporation (PRXL) is a Strong Buy at current levels. 7 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on PAREXEL International Corporation (PRXL). Zacks Investment Research suggests a Hold with a rank of 3. 1 others believe that the stock has run up ahead of its fundamentals and advise a Strong Sell on the stock.The median of all the 13 Wall Street Analysts endorse the stock as a Buy with a rating of 2.38.
PAREXEL International Corporation (PRXL) : The consensus price target for PAREXEL International Corporation (PRXL) is $70.94 for the short term with a standard deviation of $9.58. The most optimist securities analyst among the 8 who monitor the stock believes that the stock can reach $80, however, the pessimist price target for the company is $49.
Also, UBS downgrades its view on PAREXEL International Corporation (NASDAQ:PRXL) according to the research report released by the firm to its investors. The shares have now been rated Neutral by the stock experts at the ratings house. Earlier, the shares had a rating of Buy. UBS lowers the price target from $82 per share to $76 per share on PAREXEL International Corporation. The rating by the firm was issued on September 6, 2016.
PAREXEL International Corporation (NASDAQ:PRXL): After opening at $67.32, the stock dipped to an intraday low of $67.3 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $68.56 and the buying power remained strong till the end. The stock closed at $67.85 for the day, a gain of 0.47% for the day session. The total traded volume was 604,713. The stocks close on the previous trading day was $67.53.
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services, PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management, data management, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, medical imaging services, electronic data capture systems, clinical trial management systems, Web-based portals, and other product development tools and services.